🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — March 09, 2026

The IPO Pipeline stream reveals a diverse set of filings dominated by merger-related S-4s (Mission Produce/AVO acquiring Calavo, Stock Yards/SYBT merging with Field & Main) and S-1s including a post-bankruptcy shelf (Wolfspeed/WOLF), a high-debt IPO candidate, and a new SPAC (West Enclave). Period-over-period trends are sparse but highlight outlier strength in the unknown IPO candidate with operating cash flows surging 118% YoY to $480M in 2025 despite debt service outflows rising 72% YoY to $549.2M (68% of op cash). Mixed/neutral sentiments prevail amid prominent risk disclosures, shareholder approvals, and dilution potentials. Overarching themes include M&A as an IPO alternative, persistent leverage concerns (e.g., $3.98B debt in IPO candidate vs. SPAC's clean $100M raise), and post-reorg activity signaling stabilization. Market implications point to arbitrage opportunities in mergers, caution on leveraged IPOs, and watch for SPAC catalysts in LatAm-focused deals. Portfolio-level, 3/5 filings emphasize special meetings and approvals as near-term catalysts.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — March 09, 2026

Across 50 US SEC filings for FY2025 and early 2026, mixed sentiment prevails in 40+ cases, reflecting revenue volatility amid cost controls narrowing losses in biotechs (avg net loss improvement ~25% YoY in 15/20 biotechs) but widening in others due to impairments (e.g., $616M crypto losses at SharpLink). Revenue trends show stark divergence: explosive growth in select biotechs/pharma (Zevra +350% YoY, Cumberland +17.6%) contrasted by declines in healthcare staffing (-21.6% Cross Country), diagnostics (-38% OraSure), and manufacturing (-12% 3D Systems). Financials exhibit resilience with NIM expansion (Tri-County +44bps, Heritage +31bps) and ROE gains (Tri-County +1.64pp), while SPACs (8 filings) uniformly report trust interest-driven net income (avg +$4M YoY). Impairments aggregate >$2B (e.g., NET Power $1.5B, Repay $242M), signaling overvalued assets, but cash raises bolster biotechs (e.g., enGene +$151M). Capital allocation leans conservative: dividend cuts (Tiptree -51%, Caseys up 14%) and buybacks absent; M&A limited. Portfolio implication: Biotech turnarounds and regional banks offer alpha, avoid impairment-heavy cyclicals amid 2026 policy risks (EVgo OBBBA).

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 09, 2026

Across 32 DEF 14A proxy statements, the dominant theme is routine governance with 28/32 filings neutral in sentiment, focusing on director elections, auditor ratifications (e.g., PwC, Deloitte across multiple), and advisory say-on-pay votes, signaling stable board continuity amid no widespread executive pay controversies. A cluster of 13 closed-end funds (Flaherty & Crumrine, Western Asset) shows highly concentrated ownership via Cede & Co. (98-99.97%) and low director/officer holdings (<1%), indicating institutional dominance but limited insider alignment. Limited period-over-period data reveals outliers like Deluxe Corp's 10% YoY growth in Payments/Data segments (to 47% of revenue from 43%), +6% adjusted EBITDA, +10% adjusted EPS, and FCF exceeding $100M target early, reducing leverage to 3.2x; Citizens Financial Group reported top peer TSR in 2025 with $226.4B assets. Mixed sentiments in 4 filings highlight risks in SPACs (5th extension), biotechs (NeuroOne reverse split for Nasdaq compliance, Moleculin 129% dilution from warrants), tempering portfolio optimism. No insider trading activity or capital allocation changes (dividends/buybacks) disclosed across filings, with forward-looking catalysts centered on April 2026 annual meetings (15+ events). Overall, low materiality (avg 5.6/10) suggests muted near-term volatility, but monitor biotech/SPAC dilutions and governance votes for alpha.

32 high priority 32 total filings
· daily

US Executive Officer Management Changes SEC — March 09, 2026

Across 34 SEC filings on USA Executive & Director Changes from March 9, 2026, the dominant theme is proactive board expansions and executive appointments (18 instances, e.g., Phillips 66 added 2 independent directors, FTI named experienced CFO Angela Nam), signaling strengthened governance amid growth phases, contrasted by 12 departures (7 planned retirements like West Pharma CEO Eric Green H2 2026, 5 sudden like Gulfport CEO John Reinhart). Positive sentiment prevails in 14/34 filings (41%), particularly biotech/pharma (Zevra revenue +351% YoY to $106.5M, Boundless R&D -26% YoY to $9.8M Q4), while mixed/neutral in energy transitions. Period trends show cost discipline (Boundless op ex -23% YoY Q4) and revenue surges (FTI FY25 $3.8B, Zevra Q4 +184% YoY), with reaffirmed guidance in West Pharma/Planet Fitness indicating stability. No widespread insider selling; equity grants/bonuses (e.g., Alpha Omega 220% CEO max bonus) reflect alignment. Sector patterns: Energy leadership churn (4/34 filings), biotech hiring for trials/growth. Implications: Bullish for continuity hires, monitor sudden exits for volatility; portfolio-level alpha in pharma turnarounds.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 09, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive capital raising via PIPEs ($85M Korro, $30M MGNC commitment), ATMs ($100M enGene), private placements ($15M Battalion, $11M Envirotech), and debt refinancings/securitizations ($1.6B Optimum, $900M Genesis revolver), signaling liquidity crunches or preemptive balance sheet fortification amid potential distress. Sparse period-over-period data reveals cost discipline in biotech (Spruce opex -40% YoY to $36.5M, net loss improved 26% to $39M) and operational upticks (Battalion oil prod +1,200 bpd Jan vs Dec), but tightening credit covenants (ProFrac availability cut to $275M, min liquidity $45M) and Nasdaq warnings (Cypherpunk < $1 bid 30 days) underscore distress risks. Direct bankruptcy activity limited to TPI Composites' Ch11 asset sale ($20M), with forbearance extensions (Cannabist to Mar 17) and collateral pledges (Jaguar $10.8M note) as red flags. M&A/asset sales (Lisata acquisition $5/share + CVR, Alexanders $235M property) provide cash influxes, while buybacks (United Therapeutics $2B, SLM $200M ASR) reflect conviction in non-distressed names. Portfolio-level: 18/50 filings involve equity dilution, 12 credit amendments/refis (mostly neutral-positive), implying sector-wide deleveraging but vulnerability to covenant breaches; opportunities in post-sale rebounds, risks in biotech trial failures.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 09, 2026

Three US-listed companies (Longeveron Inc., Cypherpunk Technologies Inc., CIMG Inc.) disclosed critical Nasdaq listing compliance issues on March 3-9, 2026, signaling heightened regulatory risks in the 'USA Trading Suspensions' stream, with no offsetting positive financial trends, period-over-period comparisons, or operational metrics provided across filings to mitigate concerns. Overarching themes include audit committee deficiencies, prolonged sub-$1 bid prices, and outright delisting notices, all carrying high materiality (7-10/10) and predominantly negative-to-bearish sentiment, pointing to potential trading halts, delistings, and liquidity erosion for small-cap names. No YoY/QoQ revenue growth, margin expansions, or positive insider activity disclosed; instead, forward-looking cure periods (up to 360 days) offer slim windows for remediation without guarantees. Portfolio-level pattern: 3/3 companies face Nasdaq rule violations (audit independence, bid price, listing standards), a cluster suggesting broader small/micro-cap vulnerability amid market pressures. Critical implications: Immediate avoidance for long positions, short opportunities pre-delisting, and watch for suspension catalysts. Newly published filings (first 2) amplify urgency versus prior CIMG coverage.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 09, 2026

The 34 filings in the 'USA Board Room Changes' stream reveal a surge in C-suite and board transitions, with 22 CEO/CFO/COO appointments or departures and 12 board additions/resignations, signaling strategic realignments amid growth phases for biotechs and energy firms. Positive sentiments dominate (14/34 filings), driven by experienced hires like FTI Consulting's Angela Nam (scaled revenues 3.5x at prior role) and Mesa Labs' Siddhartha Kadia ($2B business oversight), while mixed/neutral tones accompany sudden exits like Gulfport Energy's CEO Reinhart (materiality 9/10). Period-over-period trends show biotech outperformance: Zevra Therapeutics revenue +351% YoY to $106.5M, Boundless Bio expenses -19% FY YoY with $108M cash to H2 2028; energy firms reaffirm strategies post-changes. No widespread insider selling detected, but capital allocation stable with reaffirmed guidance (Planet Fitness, West Pharma). Portfolio-level pattern: 70% of high-materiality (7+/10) changes are positive/neutral, implying low disruption risk but watch for CEO searches in energy/consulting. Overall, bullish for hires enhancing execution in scaling firms, bearish for leadership vacuums in mature players.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — March 09, 2026

The 14 filings reveal a surge in US M&A and SPAC activity on March 9, 2026, with 10 SPAC-related events dominating (mergers, extensions, IPO upsizes), signaling robust blank-check dealmaking amid energy, AI, and defense sectors. Key completions include Presidio Production's business combination with $87.5M PIPE and $125M preferred, CACI's $2.6B ARKA acquisition enhancing EO/IR capabilities, and MiniMed's $538M IPO proceeds post-Medtronic spin-off. Positive sentiment prevails in 11/14 filings (79%), with total announced/closed deal values exceeding $3.5B (CACI $2.6B, Calisa $180M, Presidio $212.5M PIPE+pref, MiniMed $538M). No broad period-over-period financial declines noted, but SPAC extensions (Aquaron $16K note, Ribbon $600K note) indicate deadline pressures without redemptions flagged. Mixed promo in Pelican/Greenland adds hype to energy exploration, while Trailblazer's Nasdaq non-compliance poses isolated delisting risk. Portfolio trend: SPAC de-SPACs accelerating (3 announced/closed vs prior briefs), favoring liquidity events and sector rotation into geothermal/AI/oil.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 09, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout revenue growth in biotech/pharma (e.g., ARS Pharma product revenue +890% YoY to $72.2M, Cumberland Pharma +17.6% to $44.5M) offset by widening losses and expense surges in 7/15 key 10-Ks; energy firms like W&T Offshore (-4.5% revenue YoY) and Sphere 3D (-32.5%) show declines amid commodity pressures, while SPACs dominate with 8+ merger extensions/announcements. Period-over-period trends highlight revenue expansion averaging +50% YoY in high-growth niches (BETA Tech +136%, SharpLink +666%) but margin compression and net losses in 12/20 metric-rich filings (avg net loss expansion +150%). M&A activity surges with deals like Aureus Greenway/Autonomous Power and Mission Produce/Calavo, alongside financings totaling $100M+ (e.g., Bunker Hill C$33.8M). Capital allocation leans toward debt reduction (GLDD -15.6% long-term debt) and buybacks (News Corp $1B program, GLDD $12M repurchases), but insider activity is absent across filings. Forward-looking catalysts cluster in Q1-Q2 2026 (e.g., FAA certifications, drug approvals, closings), signaling portfolio rotation opportunities from underperformers like Cross Country (-21.6% revenue) to outperformers like Great Lakes Dredge (+16.5% revenue, +28.4% NI). Overall, bullish on select biotech/industrials amid SPAC consolidation, cautious on healthcare staffing and E&P.

31 high priority 19 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 08, 2026

GardaWorld Federal Services LLC secured a $313.4M DHS/ICE delivery order for renovating and operating a detention facility in Surprise, AZ, with ceiling potential of $704.1M via options, signaling robust demand for private infrastructure in immigration enforcement. This firm fixed-price award to the BC Partners-backed firm highlights sector tailwinds amid rising detention needs. Key risks include cost overruns and execution delays, but option exercises could drive 2.2x revenue upside by 2029.

1 total filings
· daily

VA Healthcare & Services Contracts — March 08, 2026

A single massive $1.28B VA EHRM contract awarded to Oracle Health Government Services provides substantial long-term revenue visibility through May 2026, signaling bullish momentum for Oracle's government health IT segment. However, zero funds outlayed to date despite the obligation raises execution risk, warranting caution amid firm-fixed-price exposure to inflation. Investors should monitor funding releases and options exercise for near-term catalysts.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 08, 2026

Amgen USA Inc. secured a $774M HHS/BARDA contract for 10-year biotech R&D on thrombocytopenia treatments for mass casualty events, with $712M already outlayed, providing stable long-term federal revenue amid high execution. This sole award highlights concentrated BARDA support for biodefense biotech, positioning Amgen favorably but exposing it to cost overrun risks under firm fixed price terms. Investors should monitor option exercises worth $143M and potential follow-ons post-2032.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 08, 2026

Oracle Health Government Services secured a $1.28B VA contract for EHRM hosting and management through mid-2026, signaling strong long-term revenue visibility in federal health IT amid zero competition. However, zero funds outlayed despite massive obligation flags potential execution delays or funding constraints. This single large award underscores concentration risk in VA IT spending but highlights sector stability via extended firm-fixed-price commitments.

1 total filings
· daily

New Federal Contractors — March 08, 2026

New federal contracts disclose $6.17B in obligations (potential $14.2B incl. options) across 6 awards, all bullish for non-small govcon firms in DOE remediation (71% of value), defense R&D, health IT/biotech, and DHS facilities. Savannah River Mission Completion dominates with $2.37B DOE awards for 8-year Savannah River site work (potential $8.42B), signaling prioritized nuclear cleanup spend through 2031. Long-dated terms to 2032 and $5B+ in options offer multi-year revenue tailwinds amid high outlays ($2.66B already spent).

6 total filings
· daily

Significant Contract Modifications ($10M+) — March 08, 2026

Six significant contract modifications totaling $6.17B obligated value signal strong federal commitment to long-term missions, led by $2.37B DOE awards to Savannah River Mission Completion LLC for Savannah River site remediation through 2031. Unobligated options exceed $5B across contracts, offering substantial upside for contractors in remediation, defense R&D, health IT, and biotech. All awards to non-small businesses via full/open competition highlight stability for large-cap providers amid execution risks from firm-fixed pricing and low near-term outlays.

6 total filings
· daily

Contract Deobligations Alert — March 08, 2026

Six bullish contract signals totaling $6.2B in obligations highlight stable long-term federal revenue for key contractors, with DOE's Savannah River remediation dominating at ~$2.4B obligated (up to $8.4B potential) across two awards to the same LLC. Unobligated options exceed $5B across the portfolio, signaling upside in defense R&D, health IT, biotech, and security services. Long performance periods (avg. 8+ years) provide revenue visibility through 2032 amid full/open competition wins by non-small businesses.

6 total filings
· daily

Contract Option Exercises — March 08, 2026

Six bullish contract exercises totaling $6.2B in obligations signal robust federal spending on long-term missions, with DOE's Savannah River Mission Completion LLC capturing $2.4B (39% of total) for nuclear remediation through 2031. Significant upside lies in $10B+ unobligated options across defense R&D, health IT, biotech, and detention facilities. Institutional investors should prioritize contractors with multi-year visibility amid steady outlays ($2.7B already spent).

6 total filings
· daily

All DOE Contracts — March 08, 2026

DOE awarded two task orders totaling $2.37B obligated ($8.42B potential with options) to Savannah River Mission Completion, LLC under the single Integrated Mission Completion Contract for Savannah River site remediation through 2031. This concentration signals robust, long-term federal commitment to nuclear liquid waste and tank closure operations (NAICS 562910). Key upside lies in ~$6.1B unobligated options, providing multi-year revenue visibility amid stable remediation needs.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 08, 2026

Six mega contracts totaling $6.2B obligated value signal strong federal commitment to long-term projects in DOE remediation, defense R&D, health IT, biotech, and DHS facilities, with Savannah River Mission Completion capturing 40% ($2.37B) via two DOE awards. All bullish with $14B+ potential via options, providing multi-year revenue visibility through 2032 amid steady outlays in mature contracts. Investors should prioritize DOE environmental services and health/gov IT for stable cash flows, monitoring option exercises for 2x+ upside.

6 total filings